Aller au contenu principal
Fermer

Transgene reports business update and Q3 2021 financial position
information fournie par Boursorama CP 04/11/2021 à 17:45
Ajouter Boursorama à vos sources

- Data presented at ESMO in September provided clinical proof of concept for the intravenous administration of Transgene’s patented oncolytic virus (Invir.IO™ platform)—significantly expanding the market opportunity

- First data from two ongoing Phase I trials of the individualized cancer vaccine TG4050 (myvac® platform) will be communicated in the second half of November 2021

- €40.9 million in cash and cash equivalents as of September 30, 2021, further strengthened by the €17.4 million received in October 2021 from the partial sale of Tasly BioPharmaceuticals shares

- Financial visibility until the end of 2023

.../...

Valeurs associées

0,8540 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

98,45 -1,57%
8 154,91 +0,20%
Or
4 362,5 +0,16%
0,637 +20,64%
29,4 +7,57%
Chargement...